Omnicell, INC 8-K filings

Omnicell, Inc. announced solid second quarter 2026 financial results, with revenues at the high end of expectations and increased full-year guidance for non-GAAP EBITDA and EPS.

Omnicell, Inc. announced the appointment of Nnamdi Njoku as President, effective July 1, 2026, while he retains his COO role, as Randall Lipps continues as CEO and Chairman.

Omnicell, Inc. held its 2026 Annual Meeting of Stockholders, approving amendments to its equity incentive plan and certificate of incorporation, and electing new directors.

Omnicell, Inc. announced robust first-quarter 2026 financial results, driven by strong demand for its connected devices and core solutions, leading to an increase in full-year non-GAAP EBITDA and EPS guidance.

Omnicell announced solid fourth quarter and full year 2025 financial results, exceeding guidance mid-points for key metrics and launching its next-generation dispensing system, Titan XT.

Omnicell, Inc. announced the launch of Omnicell Titan XT, its next-generation automated dispensing system designed to empower autonomous medication management, powered by its OmniSphere cloud platform.

Omnicell, Inc. announced strong third-quarter 2025 financial results, surpassing previous guidance and raising its full-year 2025 outlook for total revenues, non-GAAP EBITDA, and non-GAAP EPS.

Omnicell, Inc. has adopted Fourth Amended and Restated Bylaws, enhancing procedural mechanics and disclosure requirements for stockholder nominations and proposals.

Omnicell, Inc. announced the appointment of Baird Radford as its new Executive Vice President and Chief Financial Officer, effective August 26, 2025.

Omnicell, Inc. announced strong second quarter 2025 financial results, surpassing previous guidance for revenues, non-GAAP EBITDA, and non-GAAP EPS, leading to an upward revision of its full-year 2025 financial outlook.

Omnicell, Inc. has announced an extension of Chief Financial Officer Nchacha Etta's separation date to November 15, 2025, along with the detailed terms of his severance package.

Omnicell, Inc. announced that its stockholders approved an amendment to the 2009 Equity Incentive Plan, authorizing an additional 1.75 million shares, and re-elected three Class III directors at the 2025 Annual Meeting.

Omnicell updates its second quarter and full year 2025 guidance due to reduced tariff rates and announces a new $75 million stock repurchase program.

Omnicell exceeded its first quarter 2025 guidance for total revenues and non-GAAP EPS, while updating its full year 2025 non-GAAP EBITDA and non-GAAP EPS guidance due to potential tariff impacts.

Omnicell announces that CFO Nchacha Etta will step down on September 15, 2025, while the company reiterates its first quarter and full year 2025 financial guidance.

Omnicell, Inc. has entered into an employment agreement with CEO Randall A. Lipps, extending his tenure through December 31, 2027, with adjustments to his compensation and severance package.

Omnicell reports a strong fourth quarter, exceeding previous full-year guidance for bookings, total revenues, and non-GAAP EBITDA, while also introducing new key performance metrics for 2025.

Omnicell has successfully priced a $172.5 million convertible senior notes offering due in 2029 and will use the proceeds to repurchase existing debt and fund hedge transactions.

Omnicell plans to offer $150 million in convertible senior notes due 2029 and repurchase up to $400 million of its 2025 notes.

Omnicell reported solid third-quarter financial results, including a GAAP net income of $0.19 per diluted share, and raised its full-year non-GAAP EBITDA and earnings per share guidance.

Omnicell has appointed Nnamdi Njoku as its new Executive Vice President and Chief Operating Officer, effective October 7, 2024.

Omnicell reported second-quarter results that surpassed previous guidance across all key metrics and raised its full-year 2024 outlook.

Omnicell has amended its previous 8-K filing to report that the retirement date of executive advisor Joseph B. Spears has been extended from May 31, 2024, to June 30, 2024.

Omnicell's stockholders approved an amendment to the 2009 Equity Incentive Plan, adding 2,462,000 shares, and elected three Class II directors at the 2024 Annual Meeting.

Omnicell reports first quarter results exceeding guidance while also announcing a strategic wind-down of its Medimat Robotic Dispensing System product line.

Omnicell's Chief Accounting Officer, Joseph B. Spears, will retire on May 31, 2024, and Brian Nutt will be appointed as his successor, effective March 18, 2024.

Omnicell's 2023 financial results show a decrease in revenue and a net loss, impacted by healthcare capital budget constraints, though the company anticipates market improvements and is undertaking a business review to optimize investments.

Omnicell has appointed Eileen Voynick to its Board of Directors, while also announcing the resignation of Sara White and the decision by Vance Moore not to seek re-election, leading to a reduction in the board size.